Skip to main content

Breast cancer


10-07-2020 | COVID-19 | News

New York City data suggest link between immunotherapy, poor COVID-19 outcomes

Treatment with immune checkpoint inhibitors may increase the risk for poor outcomes among patients with cancer and comorbid SARS-CoV-2 infection, indicate data from New York City in the USA.

08-07-2020 | Breast cancer | News

TRAXHER2: No support for capecitabine addition in HER2-positive breast cancer

The addition of capecitabine to trastuzumab emtansine does not improve the clinical outcomes of patients with previously treated HER2-positive metastatic breast cancer, indicates the phase 1/2 TRAXHER2 study.

08-07-2020 | Immunotherapy | News

NCCN issues patient guidelines on immunotherapy side effects

Click through for details

03-07-2020 | COVID-19 | News

Potential for anticancer, COVID-19 drug interactions highlighted

A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.

02-07-2020 | FDA | News

FDA approves outpatient combination HER2-positive breast cancer therapy

Read more on this here

01-07-2020 | Breast cancer | News

Timing of diagnosis impacts interval breast cancer prognosis

Women with interval breast cancers diagnosed within 1 year of a negative mammogram screening result have poorer disease-specific survival than those with screen-detected cancers, US study findings indicate.

24-06-2020 | Breast cancer | Highlight | News

Mental distress high among breast cancer patients during COVID-19 peak

Women with breast cancer had higher than normal levels of severe anxiety, depression, distress, and insomnia at the peak of the COVID-19 outbreak in the Hubei Province in China, study findings indicate.

22-06-2020 | EMA | News

Alpelisib positive opinion adopted for advanced PIK3CA-mutated breast cancer

Find out about this EMA decision here

19-06-2020 | FDA | News

Pembrolizumab approved for advanced TMB-H solid tumors

Read more on this US FDA decision here

12-06-2020 | ASCO 2020 | Conference coverage | News

PHOEBE shows PFS boost with pyrotinib in HER2-positive breast cancer

Combining pyrotinib instead of lapatinib with capecitabine is associated with significantly improved progression-free survival in patients who have received prior treatment for HER2-positive metastatic breast cancer, show phase 3 trial data.

11-06-2020 | ASCO 2020 | Conference coverage | News

No survival gain with early local therapy for de novo stage IV breast cancer

Individuals who present with metastatic breast cancer do not experience improvement in overall survival or other outcomes with early locoregional therapy for an intact primary tumor, according to ECOG-ACRIN 2108 trial findings.

08-06-2020 | ASCO 2020 | News

Olaparib breast cancer activity not confined to patients with germline BRCA1/2 mutations

Findings from the proof-of-principle Olaparib Expanded study indicate that patients with stage IV breast cancer and germline PALB2 or somatic BRCA1/2 mutations may benefit from olaparib treatment.

04-06-2020 | ASCO 2020 | News

Switching taxane–trastuzumab to T-DM1 shows no benefit in KAITLIN trial

Adjuvant treatment with trastuzumab emtansine does not improve outcome or reduce toxicity relative to that with a taxane plus trastuzumab in patients with HER2-positive early breast cancer, results of the phase 3 KAITLIN study show.

03-06-2020 | ASCO 2020 | News

Anthracyclines of no benefit in stage II/III HER2-positive breast cancer

Long-term follow-up of the TRAIN-2 study shows that patients with stage II or III HER2-positive breast cancer who receive neoadjuvant chemotherapy and dual HER2-blockade derive no survival benefit from the addition of anthracyclines.

02-06-2020 | ASCO 2020 | News

BYLieve suggests alpelisib–fulvestrant benefit after progression on CDK inhibitors

The combination of alpelisib and fulvestrant could be a promising option for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer who have progressed on prior CDK4/6 inhibitor and aromatase inhibitor treatment, indicate trial data.

31-05-2020 | ASCO 2020 | News

HER2CLIMB shows intracranial efficacy of tucatinib in metastatic HER2-positive breast cancer

Tucatinib, a selective HER2 kinase inhibitor, added to trastuzumab and capecitabine has demonstrated a survival benefit in patients with HER2-positive breast cancer and brain metastases in the HER2CLIMB trial, as presented at the virtual 2020 ASCO Annual Meeting.

26-05-2020 | Breast cancer | News

Long-term results of delayed intraoperative radiotherapy for breast cancer reported

A phase 3 trial has failed to demonstrate the noninferiority of delayed targeted intraoperative radiotherapy to whole-breast external beam radiotherapy in terms of local control at 5 years in patients with early-stage breast cancer, but other long-term outcomes were comparable.

21-05-2020 | Breast cancer | News

monarcHER points to chemotherapy-free care for HR-, HER2-positive advanced breast cancer

Women with hormone receptor-positive, HER2-positive locally advanced, metastatic, or recurrent breast cancer might benefit from a third- or later-line regimen of the CDK4/6 inhibitor abemaciclib in combination with trastuzumab and fulvestrant, findings from the phase 2 monarcHER trial suggests.

20-05-2020 | Breast cancer | News

HR-positive, HER2-positive breast cancer size could guide use of chemotherapy

Chemotherapy may only offer additional overall survival benefit over endocrine therapy alone for women with hormone receptor-positive, HER2-positive breast cancer size of 8–10 mm and not those with smaller tumors, report US researchers in a letter to JAMA Network Open

19-05-2020 | Breast cancer | News

TAILORx sheds light on cognitive decline in early-stage breast cancer

An analysis of the TAILORx trial has revealed early, but not sustained, cognitive decline among breast cancer patients treated with adjuvant chemoendocrine therapy relative to endocrine therapy alone.

Image Credits